

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-3 (cancelled)

4. (previously presented) The recombinant nucleic acid molecule of claim 6 wherein said nucleotide sequence encodes a fragment of at least 50 amino acids of nonstructural proteins NS3, NS4 or NS5.

Claim 5 (cancelled)

6. (previously presented) A recombinant nucleic acid molecule consisting of a nucleotide sequence encoding hepatitis C virus nonstructural proteins NS3, NS4 and NS5, wherein said nucleotide sequence is operably linked to regulatory elements, said regulatory elements comprising a promoter, enhancer, polyadenylation sequence, and a hepatitis C virus 5' untranslated region (5'-UTR).

7. (original) The recombinant nucleic acid molecule of claim 6 wherein said promoter is a cytomegalovirus promoter and said enhancer is a Rous Sarcoma Virus enhancer.

8. (previously presented) A recombinant host cell comprising a nucleic acid molecule of claim 6.

Claims 9-16 (cancelled)

17. (previously presented) A method of inducing an immune response against hepatitis C virus in a human uninfected by hepatitis C virus comprising administering to said human a recombinant nucleic acid molecule consisting of a nucleotide sequence encoding hepatitis C virus nonstructural proteins NS3, NS4, and NS5, in an amount effective to induce an immune response against hepatitis C virus.

Claims 18-19 (cancelled)

20. (previously presented) The method of claim 17 wherein said nucleotide sequence encodes a fragment of at least 50 amino acids of nonstructural proteins NS3, NS4, or NS5.

21. (previously presented) The method of claim 17 wherein said nucleotide sequence is operably linked to regulatory elements functional in human cells.
22. (original) The method of claim 21 wherein said nucleotide sequence is operably linked to a promoter, enhancer, polyadenylation sequence, and optionally 5'-UTR of hepatitis C virus.
23. (original) The method of claim 22 wherein said promoter is a cytomegalovirus promoter and said enhancer is a Rous Sarcoma Virus enhancer.
24. (original) The method of claim 17 wherein said immune response comprises a cellular response.
25. (original) The method of claim 17 wherein said immune response comprises a humoral response.
26. (original) The method of claim 17 wherein said recombinant nucleic acid molecule is in a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent.
27. (original) The method of claim 26 wherein said pharmaceutical composition further comprises a facilitator.
28. (original) The method of claim 27 wherein said facilitator is bupivacaine.

Claims 29-47 (cancelled)

48. (previously presented) The recombinant nucleic acid molecule of claim 6, wherein said 5'-UTR comprises at least the 9 most 3' nucleotides of a 5'-UTR of hepatitis C virus.